 |
| Actavis CEO Brent Saunders |
Actavis ($ACT), still awaiting the close of its $66 billion buyout of Allergan ($AGN), is on the lookout for more bolt-on acquisitions. As CEO Brent Saunders told Bloomberg, the company isn't up for any transformational deals in the short term, instead looking for buyouts in the "couple billion dollar" range. More